CA1198118A - Derivatives of cycloalka[c]pyrrolcarboxylic acids, a process for their preparation, agents containing these compounds, and their use, and new cycloalka[c]pyrrolcarboxylic acidsas intermediates, and a process for their preparation - Google Patents

Derivatives of cycloalka[c]pyrrolcarboxylic acids, a process for their preparation, agents containing these compounds, and their use, and new cycloalka[c]pyrrolcarboxylic acidsas intermediates, and a process for their preparation

Info

Publication number
CA1198118A
CA1198118A CA000424770A CA424770A CA1198118A CA 1198118 A CA1198118 A CA 1198118A CA 000424770 A CA000424770 A CA 000424770A CA 424770 A CA424770 A CA 424770A CA 1198118 A CA1198118 A CA 1198118A
Authority
CA
Canada
Prior art keywords
formula
compound
alkyl
hydrogen
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000424770A
Other languages
French (fr)
Inventor
Rainer Henning
Hansjorg Urbach
Rolf Geiger
Volker Teetz
Reinhard Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of CA1198118A publication Critical patent/CA1198118A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Abstract of the disclosure:

Compounds of the formula I

Description

- 2 - HOE 82/F 065 The present invention relates to new derivatives of bicyclic aminoacids of the formula I

[Cl~

\~ /
H,' ~ H
(7~n) \
1>~)2E~

-N' * * l CO - f~I - N~ - CH - ÇH2 - C - X ( I ) CO2~ Z

;n ~hich the hydrogen atoms at the bridgehead carbon atoms 4 and (7+n~ are in a cis or trans configuration relative to each other, and the carboxyl group on carbon atom 1 can be in a cis or trans configuration relative to the hydrogen atom on carbon atom (7+n)~ and in which n = 1, 2 or 3, R1 = hydrogen, (C~-C6)-alkyl ~hich can be optionally substituted by amino or (C1 C4~acylamino~ prefer~
ably (c1-c4)-alkanoyla~ino or benzoylam;no~ (C27C6) alkenyl, (cs-Cg)-cYcloalkylp (C5-C9~-cycloalkenyl~
tC5-C7)-cycloalkYl~(c1 C4)-alkyl, (C6-C10)-aryl or partly hydrogenated (C~ C10)-arYl, either of w~ich ,~

can be substituted by (C1-C2)-alkyl, (C1-C2)-alkoxy or halogen~ (Cs-C10)-aryl-(C1-C4)-alkyl~ the aryl radical of which can be substituted as defined above, a monocyclic or bicycl;c heterocyclic radicaL hav;ng S to 7 or 8 to 10 r;ng atoms, of which 1 or 2 r;ng atoms represen. sulfur or oxygen atoms and/or of wh;ch 1 to 4 ring atoms represent nitrogen atoms~ or a s;de cha;n of a naturally occurr;ng am;noac;d, R2 = hydrogen, (C~-C6)-alkyl, tC2-C6)-alkenyl or (C6-C~o)-aryl~(C1-C~-alkyl, Y = hydrogen or hydroxyl, Z = hydrogen or Y and Z ~ogether = oxygen, X = ~c1-CO)-alkY~, (C2'~C6)-alkenylO ~C5-C9)~cyclo alkyl, tC6-C10)-aryl which can be monosubstituted, disubstituted or tr;subst;tuted by (C1 C4)-alkyl, (C1-C4)-alkoxy, hydroxyl, halogen~ n;tro, am;no~ (C
C4)-alkylamino, d;-~C1-C4)-alkylamino or methylene-d;oxy, or ;ndol-3-yl, and to the;r physiologically acceptable saltsr Sui~able salts are in particular alkali metal and alkal;ne earth metal salts, salts ~;th phys;ologically acc~pt-able am;nes~ and salts w;th ;norganic or organic acids, such as, for example, ~Cl, HBr, H2S04, maleic acid or fumaric acid.
Aryl is preferablY understood as mean;ng, here and below~ phenyl or naphthyl~ Alkyl can be stra;ght-cha;n or branched.
Compounds of the formula I have chiral carbon atoms ,.

in the pos;tions carbon 1, carbon 4~ and carbon (7+n) and in the carbon atoms of the s;de cha;n ~hich are marked ~ith a star. The ;nven~ion relates to the R as well as the S
configurations at all centers~ Compounds of the formula I can therefore be ;n the form of op~ical isomers, d;astereo-;somers, racemates or m;xtures thereof. Those compounds of the formula I are preferable in wh;ch the carbon atQm 1 ;n the b;cycl;c ring system and the carbon atoms of the s;de chain wh;ch are marked w;th a star have the S configur-10 at;on.
Preferable compounds of the formula I are those ;n ~h;ch R1 = hydrogen~ (C1-C3)-alkyl, ~C2-C3~-alkenyl, benzyl, 4-aminobutyl, 4-methoxybenzyl or 4-ethoxy-benzyl~
R2 - hydrogen, (C1-C~)-alkyl or benzyl, and X - phenyl wh;ch can be monosubstituted or disubst;-tuted by (C1-C2)-alkyl, ~C1-C2)-alkoxy, hydroxyl, fluor;ne, chlorine~ bromine, amino, (C1-C4)-alkylam;no, di-~C1-C4~-alkylamino9 nitro or methylened;oxy or tri~
subst;tuted by methoxy.
Those compounds of the formula I are particularly preferred in which n = 1 or 2~ R = methyl, 4-methoxybenzyl or 4-ethoxybenzyl, and X ~ phenyl~ of which those in which R2 = hydrogen or ethyl are specifically mentionedD
The invent;on also relates to a process for preparing compounds of the formula I. One vers;on of the process com~
pr;ses react;ng a compound of the formula II

H~2C ~ ~ H - NH - CH - CH2 - C - X
R~ C02R2 Z ~ I I ) in ~hich R1, R2, X~ Y and Z are defined as in the formula I, w;th a compound of the formula III

<(C~23~

) H
I I I ) N/
H

in wh;ch the configuration of the bicyclic ring system and of the s~bst;tuent on carbon 1 ;s the same as in the formula I and ;n ~hich n = 1, 2 or 3 and W = a radical which can be elim;nated by hydrogenoly-s;s or under acid;c cond;t;ons, ;n particular a benzyl or a terta~butyl rad;cal, accord;ng to known amide forming methods of pept;de chem;stry, and then us;ng catalyt;c hydrogenation or a treatment ~;th ac;d to el;minate the radical W and, ;f necessary, ~he rad;cal R2 by add;t;onal treatment ~ith ac;d or base~ to obta;n ;n either case the free carboxylic acids.
Further methods of synthes;z;ng compounds of the formula I in wh;ch Y and Z together denote oxygen compr;se reacting a compound of the formula IV

` ,!

( CH 2 ) r~

H ~ ~ H

~\N ~--C02W
co - fH -- NH2 . (IY) Rl ;n ~hich the confi~uration of the bicyclic ring system and of the subst;tuent on carbon 1 is the same as ;n the formula I and in which n and R1 are defined as in the formula I, and W is defined 2s in the formula III, with a compound of the formula Y

R202C - CH = CH - CO - X (V) in which R2 and X are defined as in the formula I~ ;n a known manner in a Michael reaction ~Organikum CPractical Organic Chem;stry]O 6th EditionO page 492, 1967)9 and el;m;-nating the radical W and, if necessary, the radical R2 as described above, or reacting a compound of the abovementioned formula IV with a csmpound of the ger,eral formula VI in which R2 is defined as ;n the formula I and with a compound of the general formula VII

OHC-C02R2 X-C~-C~3 (VI) (VII) in which X is defined as in the formula I, in a known manner in a Mannich reaction (see Bull. Socu Chim. France 1973, page 625), and then eliminat;ng the radical W and, if neces sary~ the radical R2 as described above to give the free carboxyl groupsS

It is aLso poss;ble to prepare compounds of the formula I in which Y and Z = hydrogen by reacting a compound of the abovementioned formula IV as described ;n ~ Amer.
Chem~ Soc. 93, 2,897 (1971) w;th a compound of the formula ~C02~2 O = C
C~ CH2--X ~YIII) in which R2 and X are defined as in the formula I, reducing the Schiff's bases obtainsd, and then eliminating the radi-cal W and, ;f necessary, the radical R2 as described above 1D to give the free carboxyl groups~ or by reducing a compound of the formula I in ~hich Y and Z together denote oxygen, obtained by one of the above methods. Catalytic hydrogenation is preferred. The Schiff 9S bases can be reduced catalytic-ally, electrolytically or by means of reducing agen~s~ such 15 as, for example, complex boronates, preferabLy sodium boro-hydride or sodium cyanoborohydride.
Compounds of the formula I in ~hich Y = hydroxyl and Z = hydrogen can also be obtained, for example, by reducing a compound I in ~hich Y and Z together ~ oxygen 2~ and which has been obtained by one of the above methods~
This reduction can be effected catalytically with hydrogen or ~;th any other reducing agent~ such as, for example, complex boronates, preferably sodium borohydride.
The invention aLso r~lates to compounds of the formula III ' <(CH2 ) n~

4 ~7Tny C02W ( I I I ' ) in which the carbon atoms 1, 4 and (7~n~ have the same con-f;gurations as ;n the formula III, n = 1~ 2 or 3, and W' has the meaning of W in the formula III and additionally denotes hydrogen. The invention uses these compounds as starting materials in the synthesis of compounds of the for mula I, and, according to the invention~ they can be prepared by the following methods.
In one version of the synthesis, the starting mater;al is a compound of the formula IX

/ICH2 ~ n\

H )4 t7+n ~ -I

\ N / ~IX) H
in which the hydrogen atoms on the carbon atoms 4 and (7~n) are in a c;s or trans conf;gurat;on relat;ve to each other, and n denotes the number 1, 2 or 3.
Compounds of the formula IX ;n wh;ch n - 1 are known from R. Griot, Helv7 Chim. Acta 42~ 67 (1959), and those in ~hich n = 2 are known from C.M. Rice et al.~ J. Org. Chem.
21, 10687 (1955).
These compounds of the formula IX are acylated in a known manner wherebY an aliphat;c or aromatic acyl radi-cal~ preferably an acetyl or benzoyl radicaL, is bonded to '~:

the nitrogen atom, and the N-acylated compounds obtained are anodically oxidized in an aliphatic alcohol, preferably an alkanol having 1 to 4 carbon atoms, ;n particular meth-anol, ;n the presence of a conduct;ng salt preferably at temperatures wi~hin the range 0 to +40C to give a compound of the formula X

~(CH2 ) n~

N OR ~X) Acyl in ~hich n = 1, 2 or 3 and R3 = (C1-C4)-alkyl (s;m;lar to L;eb;gs Ann. Chem. 1978, page 1,719).
The result;ng compound of the general formula X ;s reacted ~ith trimethylsilyl cyanide by the method of Tetra-hedron Letters 1981, page 141 ;n an aprotic organ;c solven~
such as, for example~ in a hydrocarbon~ halogenohydrocarbon, ether or THF, at temperatures ~ithin the range -60~C to ~20C, preferably -40C to +0C, in the presence of a Lewis ac;d, such as, for example, ZnCl2, SnCl2, SnCl4~ TiCl4 or BF3 etherate, preferably ~F3 etherate, and the resulting compound of the formula XI
<~( 2 ) n~

H > < H
~N--CN

tXI) ~c~i in ~hich the hydrogen atoms on the carbon atoms 4 and 7~n are in a cis or trans conf;guration relative to each otherO

~he CN grvup is in ~he cis position relative to the hydro-gen atom on Lhe carbon atom (7~n), and n has the above ~entioned meaning, is purified and separa~ed -Frnm by-products by means o-f recrystallization or column chroma~oyraphy and then hydrclyYed under the ac~;on of ac;ds or bases ;n a known manner to g;ve a compouncl of the formula III in ~Ihich W' = hydrogen, ancl the la~er compound is esteri-fied if des;red~
The ac1d used in the acid hydrolys;s of the n;trile group is irl particular lICl or HBr~ The estcrification ;s carr;ed out here~ and belowr by using a conventional me~hod of amino-ac;d chemistry.
Compounds o-f t'ne general formula III' can also he prepared by convert;n~ a compouncd of the formula XII

r7~
( C ~! 2 ) n f G~

\~ (YII3 in ~Ihich the hydrogen atoms on the carbon atoms /~ and (7-~n) are ;n a c;s or trans conf;gurat;on, and n has the above-mentioned mean;rIg~ in a BeckInann rearran~ement by react;ng it ~;th a mine,al acicl, such asr for example, sulfuric ac;d or polyphosphoric acid, or l~ith ben~.enesulFonyl chloride 7~ or p~toluenesulFonyl chloride and a base such as trietnyl-amine into a compound .o-F the -Formula X~II

(C~l~) n l~l-J
( Y I 1 I ~

in which n has the abovementioned Mean1ng, and halcgenatirlg thls compound to give a compound of the formula XIV

~J~l Hal \/
/ ,/\~/
~Cil2) n . ~1 `
in ~Jhich n has the aboverner,tioned meaning and Hal deno-tes a halogen atomf pre-ferably chlorine or bromine Examples of suitable halogenat;n~ agents are inorgan;c ac;d halides, such as PCl5, S02Cl2, POCl3, SOCl~ or PBr3, or haloclens sucll as bromine~ It ;s advantageous to use PCl5 or POCl3 combined w;th SO~Cl2~ First an imidc halide forms as the intermedi~te, and reacts ~ith the halogenating agents men-tioned to give a compourld which is then hydrolyzed under bas;c ccnditions~ pre-ferably by using an aqueous alkali rnetal carbonater to give a compound of the rormula )IV~
rl-e compounds of the -formula XIV ar~ then catalytic~
ally reduced in a polar procic solvent, such asr for example~
an alcohol, preFerably ethanol, or a carboxylic acicl~ such as, for examp!e~ acetic acid. in tne presel-lce of an acicl acceptol~ such as~ for exarnplef sod7um acetate or triethyl~-am;ne~ ~o a compouncl o-f the forllulc! XV

~3 )!~l ,~ "."~
(C112 ~
X V >

in which n and Hal have the abovementionea meaningsO A
suital)le catalyst is~ for example, Paney nickel or pallad;um or pla.inum on an;mal charcoal.
Compounas of tht- formula Y`l can also be preparet~
directly hy halosenatin~ compounds of the forrnula XIXI by us;n9 smaller amounts of the abovement;oned halogenac;ng agents~
Compounos o-f the formula XV are con~erttd by means of the weLl-kno~ln Favorsk;i reac~ion ;n tht presence o-f a base ;nto a compoul1d o, the -formula III' in which I~J' - hydro-gen~ and .his ;s esterif;ed i-f des;redO The abovemel1tioned Favorsk-i; reaction is carried out in an alcoholic sol~ent, such as metl1arlol, etharlc!l or tert~~butanol~ or in ~later or in mixtures thereo-f, at temperacures w;thin the rangc 2C)C
to 140C, preferably bet~een 60C and 100('C. The bases used are advanta~eollsly alkali metal or alkal;ne earth metal hydrox;des, such as sod;um hydrox;cle, potassium hydrox;de or barium hytlrox;de, or alkal; metal alcoholates, such as, for example~ sodium methylate or potass;um tert. butanolate The intermed;ates of tht formula XIII can also be preparecD accordin~ to Can. '~ Chem~ ~8~ 557 (1C~60), irom unsaturatecl n;tr;les o-~ the forllula XVI

~ 13 ~

Cl~

tCE12)~ (XVI ) in which n has the abovernenticned mean;l-R~ by reacting the n;tr1les \lith malonates in a Michael add;c;on, followec1 by a reducing cyclizàtion, hydrolysis and decarboxylation.
Tl1e compounds of the forrnula IX in ~Ihich Y and Z
~ hydrogen, R1 ~ metilyl and R2 = rr.ethyl or ethyl~ and X =
phenyl, which are used as startiny materi~ls in preparing compounds of the formula I~ are known (European Patent Appli-cation No. 37,231). The compounds of the formula XI can be prcpared ;n various ways~ One version of their synchesis starts frorn 3 ketone of the abovernentioned folmula VII~ ~Ihich is reacteo in a known manner in a rlannic.h reaction with a compc,und of the abovementioned formula VI togetller with nmino carboxylates of the formula XVII

* *
H 2 N - CEl - C 2~ ~10 2C ~ C H -~ NEl - Cl i I C 2 15 (XVIX) (XVI;I) in which R1 ancl l~l have the abovementioned meanin~s~ to aive a compound of ~.he formula YVIII in uhich R2, R2~ y~ and i~l have the abovernentior)ed meanin~s~ with the proviso that i f W

denotes a hydro~el1oly-t cally detachable radical~ in particular ben2yl~ R2 must not have ~he meani!~g of l~v Xf the rad;cal ~J
is hydrogenolytically elirnint-ted ~ h the aid of ~ for example~

9~

palladium, ~hose co Inpoun ds of the for mula II are ob.a;ned in ~hich Y and Z - hydro~en. If the radical W is eliminated by neans of acids, such as, for example, trifluoroacetic ac;d or hyclrochlor;c ac;d, in an inert or~an-ic solvent~ such as, for exarnple~ dioxane~ those compounds of the forrnula II are obtained in which Y and Z together - oxygenD
Compourds of the Forlllula X~ L can also he obtained by kno~ln methods~ namely by reacting a compoul1d of the above-mentioned formula V in a M;chael addit-ion ~lith a compound of the abovernentioned formula XVII. This rne~hod is particu-Larly suitable for preparin~ those compounds oF the formula XVIII in ~lhich R1 = methylf R2 - ethyl and X = aryl.
Compounds of th~ formula XVIII are obtained as mixed diastereoisomers. ~hose diasterroisomers of the forlnula 15 X~III are preferred in which the chiral carbon atoms which are marked ~ith a star each have the S configuratiorl. These can be separated off by means oF recrystallization or chroma~
tography~ for example over silica gel. The configwrations of the chiral carbon a~oms are preserved ;n the subsequent elimination of the radical WO
Compounds o-F the abovementioned Formula IV, which are used as starting rnaterials in the preparation cF compounds of the formula I~ are obtained in a kr1ol~l rnanner From com pounds of the abovernentioned formula III by reactin~ them ~ith an N protected 2~aminocarbo~yl;c acid oF the formula XIX

V - IIN -- C~l - CO H
~1 X I X

~ 15 ~
in whicil V is a protective group anc~ has the ahovementionecl meaning. Examples of ~roups ~h;ch can be useo' as the pro-tect;ve ~our~ V~ which is set free again after completeci reac~ion, are benzyloxycarbonyl and tertO~butoxycarhorlylO
The startil1g materials of the -forrnula YII are obtainecd in a customary manner frorn tl1e kncl~n ketones of the formula XX

(CH2)~ 0 (XX) in which the hydro~en atorns on the br;dgehead carbon atoms can be in the cis or trans configuration and n has the above~
r~entioned meanings. Compounds o-f the formulcl XX in which n = 1 are know;7 from S. Devt J. Indian Chem. Soc. 30, 815 t1953), those in which n = 2 from Ar Kand1ah, Ju ChemO Soc~
922 (1~313, and those in which n = 3 from A.Mu Islam~ R~AD
15 Raphaelr J~ Chelnu Soc. 315 (1955).
The reaction o-f a compound o-f the formula II with a compound of thP formula III to prepare a compourld of tl1e formula I is effected by means of a condensat1Orl reaction whicl1 is known ln peptide chemistry and to ~Ihich dicyclo-2n hexylcarbodiimide or 'i-hydroxybenzotriazole, for example~
are added as condens;n~ a~entsO The subsequent hydlo~eno-lytic elimirlation of the rad;cal ~.J pre-ferably uses pallad1um as catalyst, while the ac;cls prefel-?bly used in the elimi-~
nation of the radica'L W nder acid,c conc~ ions are lri--fluoroacetic acid alld hydlo~en chloride.
Each of the c7bove reac~ions for pleparil1g tompc,urlds - ~6 -of the formulae III'~ IV and I preserves the configurations of the intermediates at the bridgehead atoms 4 and (7+n).
The starting mater;als of the formulae IX, XII and XIII are formed in the synthesis e;ther as pure diastereoisomers or as m;xtures of the poss;ble d;astereo;somers wh;ch can be separated from one another by chromato3raphy or crystal-l;zat;on.
Compounds of the forrnula IIIe which are prepared by the above methods are obta;ned as racemic m;xtures, and can be used as such in the further syntheses described above.
However, they can also be used in the form of pure enantio mers after the racemates have been separated ;nto the optical ant;podes by customary methodsD for example by a salt form-at;on w;th opt;cally act;ve bases or ac;ds.
If compounds of the formula I are obta;ned as race-mates~ these can l;kew;se be separated ;nto the;r enant;omers by means of customary method~, such as~ for example~ v;a salt formation ~;th opt;cally act;ve bases or ac;ds.
The novel compounds of the formula I are in the form of their inner salts. Since they are amphoteric compounds, they can form salts with acids as well as bases. These salts are prepared in a customary manner by reacting the compounds with one equ;valent of acid or base.
Compounds of the formula I, and the;r salts, have a prolonged, powerful hypotensive act;on. They are power-ful inhibitors of the ang;otensin converting enzyme (ACE
inhibitors~ They can be used to control hypertension of various etiologies. They can also be combined with other hypotens;~e, vasodilating or diuretically active compounds.

- 17 ~
Typical represen;~t;ves of tl-is class of active cornpour1d are desc ibed ;n~ for example, Erhardt~Ruschig~ ArzneiMittel [~rugs~, 2nd Edition, ~leinheim, 1972. 1hey can be adminis~
tered intravenously, subcutaneously or orally~
On oral adm;nistration the dose ;s 1-100 mg, prefer-ably 1-40 mg, per s;ngle dose for adult patients o-f norm3l weig,-t, ~Ihich corresponds to about OoQ13~1~3 mg/l;g/day~ pre~
ferably 0~013~0~53 mg/kg/dayO In severe cases the close can be ;ncreased, sincè toxic properties have not so far been observed~ lt is also possible to reduce ihe dose~ ~Jhicl reduction is apprcpriate in particular when diuretics ar administered at the same time~
Compounds according to the ir~vent;on can be admin;~
stered Grally or parenterally ;n the appropriate pharrna~
ceut;cal forrnulation. For an oral form of administr.ltior1~
the active compounds are mixed ~lith the add;~ives customary for this purpose, such as excip;ents~ stabil;zers or inert d;luentc, and are adrninistered by customary methods in suit-able administration forms, such as tablecs, coated tabletsf hard gelatine capsules aqueous~ alcoholic or oily suspensions or aqueous~ alcol1olic or o;ly solutions. Examples of materials hich can be used as inert excipients are ~um araibic, magnesium carbonaie~ potass;um phosphate~ lactoseO glucose and starch, ;n part;cular corn starch~ and they can be formulated not X5 only as dry but also as moist granules~ Examples of suitable oily exc;p;ents or solvents are ve~etahle and animal oilsr such as sul-,flol:er o;l or cod liver oilO
To administer theln suhcutaneously or in~ravenously the active cornpounds or their physiologically acceptal-)le - 18 ~
salts are dissolved, suspr-nded or emulsified, if desired together with the substarlces customary for this purpose, such as solub;lizels, emulsifiers or further auxiliaries.
Exarnples of materials which are suitable for use as solv~nts for the new active compounds ancl the corresponding physio-logically acceptable saLts are h~ater, physiological sodiurn chloride solu~ions and alcohols, for example ethanol, pro-panediol or glycerol, and also sugar solutions, such as glucose or mannitol solutions, or even a mixture of the various solvents mentiol1ed.
The reMarkably po~erful activity of the compounds of the formula I is supported by the pharmacoLog-ical data of the table below:
intraduodenal (i.d.) or intravenous (i~v.) adrlini-stration to anesthetized rats; 50~ inhibitlon o-f the pressor reaction triggered by 310 mg of angiotrlnsirl I 30 minutes after administration in the dose .... = ED50:
Tabl~
All thé compounds listed haveX = phenyl and R1 =

methyl.
n Y ~ R2 Configurationofthe ED (mg/kg) bicyclicr~-~iety 50 1 H ~ C2H5 1S~ 4S, 8S 0.8 (i.d.) 1 H H H 1S, 45, 8S 0.2 (i.v.) 2 H H C2H5 1S, 4S, 9S 0.6 (;.d.) ll ll C2H5 1S, 4S, 10S 1.8 (i.d.) I H H C2 5 1S, 4R, 8S 1.0 (i.d.
2 H H H 1S, 4R, 9S 0.3 (i.v.) 2 H 2 5 1S, 4R, 9S 1.2 (i.d.)
3 H H C2ll5 1S, 4R, 10S 2.1 (i.d.) 3 H H H 1 S, 4S, 1 O`S 0 . 5 ( i . V . ) 3 1I H H 1S, 4R, 10S 0.6 (i.v.) 1 - 0 -- C H 1S, 4S, 8S 1.1 (i.d.) 2 - 0 - C2H5 1S, 4S, 9S 1.4 (i.d.) The symbols n, X~ Y~ Z, R1 and RZ relate to compourlds of the formula I.
The examples ~Ihich -follow serve to illustrate the ;nvention ~I;thout restricting it to the compourlds merltioned as representatives.
Exarnple 1 t~)-(1S,~tS,~S)~OctahydrocyclopentaCc]pyrrole~1~carboxylic acid a) N-Acetyl cis-octahyclrocyclopenla~c~pyrrole 201 ml of acetyl chloride are added drop~Jise at 0C
to a solut;on of 3 g of octahydrocyclopenta~c~pyrrole and
4~2 ml of triethylamine in 30 ml of dry te~rahydrofuranD
When the mixture has been stirred at 0C for 15 m;nutes, it is diluted ~ith 150 ml of ~Jater, acidi-fied ~Jith 1 N hydro-chloric acid~ and extracted with methylene chlorideL The organic phase is dried and concentrated. The crude product is distilled under a high vacuum~
Yield: 2.~i 9; boiling point 71CtO.2 mmO
b) N~Rcetyl-2-methoxy-cis-octahydrocyclopenta'.c~pyrrole 2.~ g of N-acetyl cis-octahydrocyclopentaCc~pyrrole are anodically oxidi~ed in methanol in the presence of tetra-methylamMonium tetrafluoroborate in accordance with the information in Liebigs Annu Chemu 197~~ page 1,719. The solvent is removed, the residue is taken up ;n ether~ the mixture is filtered, and the -filtrate is concentratedu ll-NI~ data: 3~33 ~ 3.27 ~2s, OC~13) 201Z ~ 2.06 (2s, COCH~) ~ 20 -c> t~) ~15,4Sf8S)~ Acetyl~octahydrocyclopen~2~c:1pyrrol.e-1-carbonitrile 1.31 g of -crime~llylsilyl cyanide in 3 ml of methylene chloride are added at ~ 0C to a solution of 2u~ 9 of N~
S acetyl-2-methoxy-cis-octahydrocyclopentatc~pyrrole in 15 ml of rnethylene chloride~ 9 of boron trifluoride etherate are then added dropwise, and the termperature rises to -~0C~
After 2 hours a. -20C and 2 hours a-f 0C wa~er ;s added, and the mixLure ;s extracted three times w;th methylel)e chlorideO
The organic phase is washed Witll sodium bicarbonate solution and water as well as with saturated sodium chloride, and dr;ed, and the filtrate is concentrated~ This gives 202 g of the title compound in the form of a colorless oil.
d) (_)-(lS,~S,~S)-OctahydrocyclopentaCc~pyrrole-1~carboxylic acid 2.2 cJ of (_)-(1S~Sr8S)-N~acetyl~octahydrocyclopenta~
[c~ carbonitrile are heated at tlle boil for 2 hours in ml of concentrated hydrogen bromicleO Tt7e hydrogen brom;de is distilled of-F, the residue is stirred with a small amount of acetone~ and the solids are filtered off with suction.
An aqueous soLution of the product is adjusted to pH c;~n with a weal~ly basic ion exchange material. The ion exchange rnaterial is filtered off, the solution is evaporated, and the residue is filtereo' througll silica gel with a mixl:ure of methylene chloridef methanol, ~cllacic7l acetic acid and water in a racio of 20 ~ 10 : ODS 0~5~ The el.uate is con~
centrated~ and the residue is triturated with diisopropyl etherD
Yield: 1.~ g; rnelting point 1')0 - 1~50Co If the procedures described under Example 1 are folLowed, the compounds mentioned below under Example 2 and Example 3 are obta;ned:
Example 2 (+)-(1S,4S,8S)-Octahydro-2H-cyclohexaCc~pyrrole~1~carboxyliC
a _ a) N-Acetyl-cis-octahydro-ZH~isoindole 1H NMR data (CDCl3): 1.0 to 2.3 (m, 10H~
2.0 (2s9 3l~) 3.3 to 4.2 (m~ 4H) b) N-Acetyl-1-methoxy-cis-octahydro-2H-isoindole 1H NMR data tCDCl3): n.s - 2.6 (m, 10H) 2c1 ts, 3H) 3.3 (s, 3H~
3.5 - 4.0 (m~ 2H3 4.7 - 5.5 (m, 1H) c) N-Acetyl-1-cyano-cis-octahydro-2H-iso;r,dole H NMR data (CDCl3): 1.0 - 3.0 (m~ 10H) 2.0 (2S, 3H) 3~3 - 3.9 (m, 2H) 4.4 - 4.7 (m, 1H) d) tt)-(lS,4S,9S)-Octahydro-2H-cyclohexaCc~pyrrole-1-carboxyl;c acid 1H NMR data (D20): 1.0 - 3.5 tm, 12H) 3.8 ~ 4.3 tm, 1H~
Example 3 t~)-t1S,4S,10S)-DecahydrocYclohePtaCc]pyrrole-1-carboxylic a _ a) N-Acetyl-cis-decahYdrOcycloheptacc]pyrrole i . i .

1H NMR data (CDCl3)- 1.0 - 2~4 (m~ 12H~
?.0 (2s, 3H) 3.3 - 4.2 ~m, 4H) b) N-AcetyL 1-methoxy-cis-decahydrocyclohepta~c]pyrrole 1H NMR data (CDCl3): 0.9 - 2.5 (mO 12H) 2.1 (s, 3H~
3.3 (s~ 3H) 305 - 4.0 (m, 2H) 4.7 - 5.5 (m, lH) c) N-Acetyl-1-cyano-cis decahydrocyclohepta~c]pyrrole 1H NMR data (CDCl3). 1.0 - 3.0 (m, 12H) Z.O (2s, 3H~
303 ~ 3.9 (m, 2H) 4~4 - 4~7 (m, lH) d) (t)-(1S,4S,10S)-DecahydrocycloheptaCc~pyrrole-1-carboxyl;c ac;d 1H NMR data (D20~: 0.8 - 3.4 (m, 14H~
3.8 - 4.3 (m, 1H) Example 4 ZO (~)-(lS~4S,9S~-Octahydro-2H-cyclohexaCc~pyrrole-1-carboxylic acid a) Cis-octahydro-2H-isoquinol;n-3-one 41 9 (0.24 mole) of benzenesulfonyl chloride are added to a mixture of 33.6 9 ~0~22 mole~ of cis hexahydroindan-2-oneoxime and 300 ml of 5 N sodium hydroxide solution, the temperature be;ng kept below 50Cu One hour after the addit;on has ended, the m;xture is extracted ~ith methylene chloride, and dried, the filtrate is concentrated, and the residue is sublimed at 100-110C/20 mm7 ~ 23 --Y i e l a': 2 0 9; In e l t 1 n 9 p o; n t 1 4 9 ~ 1 5 1 C .
bj 4r4-D;chloro-cis octahydro-2H~-isoqu;nol.;n-3 one 28.8 g of phosphorus pentachloride are added at room ternpera~ure to a solut;on of 23 9 of c;s oclahydro--2~iso-qu;nolin~3-one ;n 350 ml of anhydrous chloroform. 43.1 g of sulfuryl c~lor;de in ~5 ml of anhydrous chlorofor~l are added dropwise at 20 to 30C ;n the course of 30 minutesO
and the reaction mixture ;s stirred at the bo;l for 5 hours~
The m;xture is left to stand overn;ght, and then neutral;~ed with aqueous potassium chloride wh;ch has been cooled to 0C. The aqueous phase is extracced ~w;ce w;th methylene chloride~ The combined organic phases are dr;ed over sodium sulfate~ and concentrated. The residue is recrystallized from ethanol ;n the presence of active charcoal~ ~his gives 32 9 of pale yellow crystals.
c) 4-Chloro-cis-octahydro~211-isoqu;nol;n~3~one 15.9 9 of ~,4-d;chloro cis-octahydro--2H-isoqu;nolin 3 one are hydrogenated at 20 to 25C in 1 liter of ethanol in the presence of 10 ml of triethylamine and Raney n;ckel under atmospheric pressure unt;l 1 mole equivalent of hydro-~en has been absorbedc The catalyst ;s f;ltered off, the filtrate is evaporated, the res;due is taken up in ethyl acetate, and the solution is extractecl twice wlth water and dried over sodiuM sul-rate~ The solvent is removed, and tl-e product is triturated with d;;sopropyl e~cher~ and f;ltered with suct;on~ This gives colorless crystals of the t;tle compouncl~

d~ (~)D(1S,~4~9S)~Octahydro 211-cyclohexaCc~pyrrole-1-carboxylic acid 3.75 (~ of 4-chloro~c;s-octahydro-211-;soquinolin~-one are added to a boilin~ solution OT 6a63 9 of bariurn hydroxide octahydrate in 120 ml of waterO 'The reaction mixture is rei'luxed For 3.5 hours~ 0~9 ml of concentrated sulfuric acid are added, and the r',ix.ure is heated at the boil for a further houl, and then lef~ to stand overni~ht to induce coagula~ion.
The pr~c;pitate which is fGrmed is filtered ofF ~ith suction, and the filtrate is adjusted to pH 605 and then evaporated to dryness. The residue is extracted ~ h boilin~
ethanol, concentrated~ and made to crystalli~e.
Yield: 3.1 9 (identical to the coMpouncJ describe(l in Example 2d~).
E~ample 5 ~ (1S,4R,~S)-Octahydro 2H-cyclollexa[c:lpyrrole~1-carboxyl;c acid a) trans-Octahydro-2h-isoquir\olin-3-olle 14.1 9 of trans-hexahydroindall~2-oneoxime are reacted with 17.2 ~ of ben7encsul-fonyl chloride in a manner similar to Example 4a) to ~ive 8 ~ of the title sompound;
melt;ng point: 165 167C.
h) 4,4-~Dicllloro-trans octahydro 2H~isoquinol1n~3-one 7.1 9 of trans-oc-tahydro~2H isoquinolin-3 one are reacted w;th 8~9 9 of phosphorus pentachloride and 14 ml of sulfuryl chloride in a manner sim1lar to Ex~ample 4b~ to give 11 ~ of the title compo~lnd. pale yelloll crystals~
melting point: 133 13'7~'C.

~ 25 -c) 4~Chloro-tralls~octallydro 2H-isoqulnolin 3-one 8 9 of 4~4 dichloro-tralls-octahydro-~2il isoquinolin~
3~one are hydrogenated ;n a manner s;rnilar to Example 4c) to ~ive 5 g of the t;tle compound~
5 d) (~)-(1Sr4R~9C.j-Octahydro 2H~cyclohe~a[c~pyrrole-1-carboxylic acid 4.2 ~ of 4-chloro~trans-octahydroY2H~isoqu;nol;n-3-one are converted in a manner similar to Example 4d) into 3.4 g of the title compound in the form of a colorless, 10 amorphous po~lder.
1H r~lilR data (D~n) 0 ~ - 3.~ (m, 12H) 3.6 4~3 (m, 1H) The aminoacids which follow can be prepared ;n a manner similar to the procedure described in Exarnple 4a) to d).
Example 6 (_)-(1S~4S~8,S~-Oc~ahyclrocyclopentaCc3pyrrole~1-carboxylic acid Colorless crystals, rneltin~ poin~c 190 - 195C (identi~
cal with the cornpouncl describecl in Exarnple 1d)).
Example 7 ~ (1S,4Rr~3S)-Octahydrocyclopen~aCc~pyrrole~1 carboxylic ac;d Colorless, amorphous powder.
1H r~lMR data (D20): 009 3~2 (rn, 10H) 3~5 ~ 404 (m~ 111) Example 8 ~ 1S,4S~1~5)-Dec~hydrocycloheptaCc]pyrrole 1 carboxyl-ic acid Colorless~ arnorphous pouder.
1H N~llR data (D20?: 1.0 - 3e4 (rn; 14H) 3~ 4~4 tmf 1H) Exarnple ~
(~ (1S~'tR~10S)-DecahydrocycloheptaCc~pyrrole 1-carboxylic ac;d 10 Color.essf amorptlous powderO
H NMR data (D20~: 1uO - 3.6 (In~ H) 3.7 4.1 (rn, 1H) Example 10 Benzyl t~)~(1S,4S~S)-octahydrocyclopentarc~pyrrole~1 carboxylate hydrochloride 0~7 cg of (~)-(1S,';S,~S)-octahydrocyclopentaCc]pyrl-ole-1-carboxyl;c acid is added ac -5C to a solution, prepared at -~tOC, of 0.7 ml of thionyL chloride in 7 rnl of benzyl alcoholL
The mixture is reacted at room teMperature for 20 hours, the benzyl alcohol is rernoved~ and the residue is triturated with diisopropyl ether~ This ~ives 0~84 9 of the title compound in the forrn of colorless crystals ~hicll n~elc at 120 -~ 122C.
1H NM~ daca (DMS0--d6)~ 2~3 (mf ~H) 3~2 3~7 (m, 2H) 3~8 ~ 4O2 (m~ 1H) 5~1 (s, 2Hj lhe follo~ing benzyl ester deriva~ives of Examples 11 to 15 can be prepared ;n a manner s;m;lar to the procedure described in Exarnple 10:
Exampl.e 11 Benzyl ~:t)~-(1S~4S,9S)~oc~ahYdrocYclohexaCc~PYrrole~1 carbo~ylate hydrochloride 1~1 r~Mr~ data ~D~lS0-d6) 1.1 - 2,4 (m, 10H~
3.2 - 3.7 (m~ 2H) 3.8 - 4L3 tlll, 11~) 501 (s, 2H~
7.2 (s~ 5H) Example 12 Benzyl (~)-(15~4S,1QS) decahydrocyclohep~a~c]-1~carboxylate hydrochloride 1H N~lR data (DMSO-d6) 0~9 2.4 ~m, 12H) 3.2 - 3.7 (m, 2H) 3.8 - /~.4 (m, 1H) 5.1 (s, 2H) 7.2 (s, 5~1) Example 1-.
2n Benzyl (t)-(1sr~Rr8s)~octahydrocyclopentaic:lpyrrole~1 carboxylate hydrochlor1de 1~1 NP~R data (DMSo-d6) 10~ - 2D2 (m, 8H) 3.0 ~ 307 (M, 21~) 3.8 ~ 4~4 (m, 111) . 5.2 (s, ~
7.2 (sr 5~-1) Exarnple 1~.
Benzyl (~ 4R~9S)-octahydrocyelohexarc~pyrrole-1-carboxylate hydrochlor;cle ~ MR data (DMSO-d6) 1~1 - Z~2 (In~ 1C~I!) 3.0~6 (Ill~ 2~) ,,6 (alO 1~) 5.1(s, 2H) 7~2(s~. 5 Example 15 Benzyl (t)-t1S,4R~10S)-decahydrocyclohepcaCc~pyrlole-1-carboxylate hydrochlor;de 1H NMR data (DMS0-d~): 1O0 - 2.4 (m~ 12H) 3uO o 306 (m~ 211) 3~7 - 4O4 (m~ 1H) 5.1 (sr 2l-1) 7u~ (s, 5l~) Exan~ple 16 TertO-butyl (t)-(1S,,4S,8S)-oGtahydrocyclopentaCc:lpyrrole~
1-carboxylate hydrocllloride 2n 10 ml of concentrated sulfuric acid and S0 ~ of ;sobutylene are added to a solution of 10 g of (t)~(1S,4S,SS) octahyclrocyclnpentaCc3pyrrole 1-carboxylic acid in 100 ml of dioxane and vhich has been cooled down to -10C. Tl)e react1On mixture is graduall~ warmed in an autoclave to 20 to 25C, and stirred at th;s temperature for 20 hoursr The m;xture is added to ice cold 50% strength aqueous sodiunl hyc~roxicle, and the resultin~ mixture is ex'cracted with me'chylene chlorideG l'he combined organic phases are washed with uater~ dried with sod;um sulfate~ and concentrated~

The residue i~ taker, up in ether~ and the solut;on is adjusted to pH Z~0 to 3~0 by means of ethereal hydroJen chLoride.
The rnixture is evaporated ~o dryness, and the product is tritllrated wi~n diisopropyl ether~ Filteriny wlth suctiGn then gives 7.3 9 o-f the ti-tle compouncl.
1H N~lR data (DMS0~d6) 1.0 - 2.4 tm, ~H) 1.3 (s, 91-i) 3 ~2 ~ 3 n O ~m~
3~8 - 4.4 (m, 111) The ter~ butyl esters of Cxanlplex 17 to 19~ wh1ch follo~, can be prepared in a sirrlilar manner.
Example 17 Tert.~butyl (~)-(1S~4S,9S)~octahydrocyclonexa~c:lpyrrole~
carboxylate hydrochloride ~H N~lR data (DMS0-d6~: 1.1 2r7 (m, 10H) 1.3 (s, 9H) 3.2 - 3.7 (m, 21-1) 3.8 - 4.5 (rn~ 1H) Example 1~
Tert. butyl (~-) (1S,4R~8S)-octahydrocyclopenta~c]pyrrole--1-carboxylate hydrochloride lR data (D~`lSo-d6' 1.1 - 2~8 (mr ~H) ~ (s~ 91-1) 3.2 ~ 3.6 (m, 2H) 3.7 - 4.5 (m~ 1H) Exarnple 1~
Tert.^b~tyl ( )-(1S~4R~S)~oc~ahydrocyclol,exa~c]pyrrole 1-carboxylate hydrochloride H tJ~lR data ~DMSO~d6) 1.1 3~0 (m~ 10H) 1~3 (s~ 9H) 3n1 ~ 3~5 (m~ 2~1~
3.7 ~ 4.5 (rn~ 11-l) Exanlplr.! 20 ~enzyl r~l ~1S~carbethoxy~3-pherlylpropyl)~S-alanyl 1s~4Sr~S~
octahydrocyclopentaCc]pyrrole 1~-carboxylate (~~ cl;astereo-1sor,ler A 20) and ben~yl N~(1S~-carbethoxy 3 phenylpropyl) S alanyl~1R"~R,~R-octahydrocycl~pentaCc:lpyrrole~1-carboxyl~
ates (= diastereo1somer B 20) 0~82 g of N-(1S~carbethoxy-3~pllenylpropyl)-S~alar,ine~
0.39 g of 1~hydroxybenzotria~ole, 0.~,2 g of benzyl (~ 1S,~S,SS) octahydrocyclopenta~c~pyrrole 1-carboxylate hydrochlor;de~
0.5 ml of N--ethylmorphol;ne and 0.59 g of dicyclohexyl carbo diirn;de are added at 20C to 4 ml of dimethyl-formalnide~
15 The mixture is stirred for 3 hours~ diluted ~Jith 50 ml o'r ethyl acetate, extracted tw;ce ~ith water~ drled over sodiurn sulfate, and concentrated~
~ his gives a mixture of the abovemen~.loned diastereo-isonlers A 20 and B 20~ which are separated over silica ~el witll a mixture of cyclohexane/ethyl acetate (Z~
R~ value for cdiastereo;somer A 20~ 0O22 R~ value For diastereo;sorner B 20 0~20 The compounds of Exarnples Z1 to 29~ which foli.o~, are prepared in a manner similar to that describec! in Example ~t~

Example 21 Benzyl N~ S-carbethoxy-3-phenylpropyl)-S-alanyl-1S,4R~8S-octahydrocycLopentaCc~pyrrole-1-carboxylate (= diastereo isomer A 21) 5 1H NMR data (CDCl3): 1.25 (d+t 6H) 1.3 - 2~4 (m, 10H3 2.3 3.4 (m~ 6H) 4~1 (9, 2H) 4.6 (d~ 1H) 10 5.Z ~s, ZH) 7~2 (59 5H) 7.4 (s, 5H) Example 22 ~n~yl N-(1-S-carbethoxy 3-phenylpropyl)-S-alanyl-1S,4S~9S-octahydrocyclohexaCc]pyrroLe-1-carboxylate (= d;astereo ;somer A 22) 1H NMR data (CDCl3): 1.1 (d~ 3H~
1.3 (t, 3H) 1.4 - 2~5 (m, 1ZH) 2~3 - 3.4 (m, 6H) 4.2 (q~ 2~13 4.5 (d, 1H) S.1 (s, 2H) ~.2 ~s~ 5H) 25 7.35 (s~ 5H) Example 23 8enzyl N~ S-carbethoxy-3-phenylpropyl)~S-alanyl-1S,4R,95-octahydrocyclohexaCc~pyrrole-1-carboxylate (= d;astereo-isomer A 23) 5 1H NMR data (CDCl3): 1~2 (d~t, 6H) 1~3 - 205 (m, 12H) 2~3 - 3~4 tm~ 6H3 401 (q, 2H) 4.5 td~ 1H3 5.2 (s~ 2H) 7.2 (s, 5H) 7.35 (s, 5~) Example 24 Benzyl N-t1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1S04S~10S
decahydrDcyclohepta~c]pyrrole-1-carboxylate (= diastereo-;somer A 24) 1H NMR data tCDCl3): 1 n2 td~t~ 6H) 1~3 2.6 ~mO 14H) 2.3 - 3u4 ~m, 6H) 4.1 tq~ 2H) 4.6 (d, 1H) 5~2 ts~ 2H) 7~2 (s~ 5H) 7.4 (s, 5H) 25 Example 25 ~enzyl N-(1-S-carbethoxy 3-phenylpropyl)-S~alanyL-1S,4R~10S-dehydroeyclohepta~c]pyrrole 1~carboxylate t= diastereo~
isomer A 25) 1H NMR data (CDCl3): 1.25 (d~t, 6H) ~rl . ~ .

1,3 Z.5 (m, 1411) 2.3 - 3.4 (mO 6H) 4~5 (d, 1H) 5~2 (s~ 2H) 7.2 ts~ 5i~) 7.4 (s, 5H) Example 2b TertO~butyl N~ S-carbethoxy-3-phenylpropyl)-S-alan~l-1S~S,~S octahydrocyçlopenta~c~pyrrole~1-carboxylate (= çdiastereoisomer A Z6) 1H N'MR data (CDCl3): 1.25 (d~t, bH) 1.3 (s~ 9H) 1~3 2,6 (.m; 1nH~
2~3 - 3.4 (m, 6h') . 1 ( q ,, ~
~1.6 td, 1H) 7.2 (s~ S~l) Example 27 20 Tert.-butyl N-(1~S~carbethoxy-3-phenylpropyl)-~S alarlyl~
1S~4S,~iS-octahydrocyclohexa~c:lpyrrole~1-carboxylate (= d;astereo;somer A 27) 1H NMR data (CDCl3): 1.25 (d-~t, 6H) 1~3 (s~ 9H) 1.3 2.4 (In~ 12H) 2 r 4 3 ~ 5 (m~
4.1 tq, 2H) 4.6 tcl, 1il) 7~2 (s~ S~l) - 3~ -Example 2B
Tert. bu~yl N~ S-carbe~hoxy-3-phenylpropyl)~S~alanyl~
1S,~R,8S-octahydrocyclopentatc]pyrrole-1-~arboxylate (= diastereo;somer A 28) H NMR data (CDCl3) 1.25 (d~t~ 6H~
1.3 (s, 9H) 1~3 - 3~5 (m, 10H) 2.5 - 3.5 (m~ 6H) 4.1 (q, ~H) 4.55 (d, 1H) 7.2 (s~ 5H) Example 29 TertO-butyl N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1S,4R,9S-octahydrocyclohexa~c~pyrrole-1-carboxylate t- diastereoisomer A 29~
1H NMR data tCDCl3): 1.25 td+t, 6H) 1.3 (s, 9H) 1.3 - 2.6 (m, 12H) 2~ - 3.~ (m, 6H) 4.1 (q, 2H) 4.5 (d, 1H) 7.2 (s, 5H) Example 30 N-t1-S-Carbethoxy 3-phenylpropyl)-5-alanyl-15,45,8S-octa hydropenta~c~pyrrole-1-carboxylic acid hydrochloride Method A:
0.7 g of diastereoisomer A 20, of Example 20, is hydrogenated at 2D to 25C under atmospher;c pressure in 25 ml of e~hanol ~ith 100 mg of pall.ad;um an;mal charcoal - ~5 -(10/~)~ The ca~alyst is separated of;~ and O.S n ethanolic hydrogen chloride is added to the s,lution un~il it reacts acidicO The solution is concentrated in vacuo, and the residue is tr-iturated with di;sopropyl ether~ This gives 400 rng of the title cornpound in the form oF an amorpl-lous powder.
1H NMR data (DMS0 d6~ 1.25 (d~t~ 6H) 1.3 - 2.~ (m~ 101-l) 2.~ - 3O7 (mr 6H) ~1 tq~ 2i1) 4u4 (d, 1H) 7.2 (s~ 5~) Method B:
A solution o-f 0.8 9 of diastereoisomer A 26~ of Example 26, in 5 ml of methylene chloride is saturated uith dry hydrogen chloride ~as, and then le-ft to stand at 20 to 25C for 16 hoursO The solution is concentrated in vacuo;
the residue is triturated with diisopropyl etherO and fil-~tered with suction.
Yield: 550 mg.
Example 31 N~ S Carbethoxy~3~-phenylpropyl) S alanyl-1R,4R~8R oc~a hydrocyclopenta[c~pyrrole-1~carboxyl1c acid hydrochloride This compound is obtained frorn the diastereoisorner B 20 of Example 20 in a manner similar to that oF method of Exarnple 30. Colorless crystals of melting point 185 1 ~8C

Example 32 N--(1 S-^Carbethoxy-3 phenylpropyl)-S~alanyl~1S~4R~S-octa-hydrocyclopentaCc~pyrrole~ carhoxylic acid hydrochl.orîde This compound is obtained from the diastereo;sonler A 21 of Example 21 ;n a manner similar to that of metilod A of Example 30.
1H NMI data (CDCl3): 1.2 (d-~, 611) 1~3 ~ 2r4 (m, 1nl~) 2.4 3.7 (m~ 6~) 4.1 tq, 2H~
~ .b (dr 1 H) 7~2 (S~r 51 Example 33 t~i~(1 S~Carbethox>~3 phenylpropyl)-S~alanyl--1$~S~9S~octa~
hydrocyclohexai~c]pyrrole 1-carboxylic acid hydrochloride This coMpound is obta;ned f-rom the diastereo,somer A 22 of Exa~ple 22 ;n a manner similar to method A of i--xclmple 30.
1l~ N~lR data (D~1S0 d6) 1.3 td ~ 611) Z0 1.3 - 2.4 (m~ 12H) 2~4 - 3.7 tm~ 6il) 4.1 (q~ 21-i) b~4 (d, 1l~) 7.2 (s, 5H) 25 Example 34 N~ S~Carbethoxy-3-pllellylpropyl)-S-alanyl 1S~4Rf9S-octa c~c~O
hydrc~lexaCc]pyrrole-1 carboxylic acid hydrochloride ~his compound ;s obta;ned from tile d;as-cereoisomer A 23 o~ E ample 23 in a manner similar to method A o-. Exampl.e 3~

- 3~
1H NM~ data ~PMsO~d6) 1.3 (d:t, 61~?
103 - 2.f~ (In~ 12H) 2.4 3.7 (m, 6H) 4.1 (q, 2H) ~.45 (d, 1l-l~
7.~ ~s, 51~) The compounds of ExaMples 32 to 34 can likewise be prepared from the diastereoisomers A 26 to A 2~ by the rnethod B described in Example 30r Example 35 N-(1 S-Carbethoxy-3-phenylpropyl)-S-alanyl-1Sr4Sr10S-deca-hydrocyclohepta[c~pyrrole 1-carboxyl;c acid hydrochloride This compound is obta;ned from the d;astereoisomer A 24 of Example 24 in a manner sirnilar to methoa' A of Example 30.
H NMR data (D~lSO~d6): 103 (dlt, 6H) 1Y3 - 204 tm, 14H) 204 - 3Y7 (m~ 6~1) 4.1 (q, 2l-1) ~.6 (d, 1h') 7.2 (s, 5H~
Example 36 N~ S-Carbethoxy-3-phen~lpropyl)-S~alanyl-1S~4R~.10S-deca-hydrocyclohepta~c pyrrole~1-ca.boxylic acid hydrochloride 25 This compownd is obtained from the diastereoisomer A 25 of Example 25 in a manner s;milar to method A of Example 3~0 1l~ NrlR data (DMS0 d6) 1.3 (d~t~ 6H) 1.3 - 2~5 ~m~ 1~iH) 2uS ~ 3.7 (m, 6H) 4.1 (q. 2H) 4.4 (d~ 1H) 7.2 (s, 5H) Example 37 S--Carboxy~3-phenylpropyl)-S~alanyl~1Sr4S,8S-oc-tahydro-cyclopenta~c~pyrrole 1-carboxylic acid Two ec~uivalellts of potassium hydrox;de and a 10X
strength excess oF 4n potassium hydroxid~e solution are added to a solution of 1 9 of N~ S-carbethoxy~3~phenylpropyl)-S-alanyl~15~4$~8S-octahydrocyclopenta~c~pyrrole~1 carboxylic acid hydrochloride in 10 ml of watern The reac~ion solutior, is stirred at 20 to 25C for 8 hours, then adjusted to pl-l b ~n w;tll 2 N hydrochloric acid~ and concentra~ed in vacuou The residue ;s taken up in ethyl acetate; precipitc\ted salt ;s filtered off~ The ethyl acetate solutic,n is concentrated~
and the res;clue i~ triturated ~ith diisopropyl ether and filtered off w;th suct;on.
Yield: 0.6 gO
2n 1 H NMR data (CDCl3) 1.2 (d, ~H) 1~2 3~8 (m~ 16H) 4~0 ~ 406 ~mr 1H) 7~2 ts, S~
Example 3 N (1-S-Carboxy 3~phenylpropyl)-S-alanyl-1S~4R~S-octahyclro~
cyclopenta~c~pyrrole~1 carboxylic acid Th;s cornpound ;s prepared Frorn the compound of Example 32 in a method similar to that described in Example ~8~
39 ~
1H NMR data (CI~Cl3): 1.25 (d~ 311) 1.3 - 3uq (m 16H) ~nO 4~6 (rn~ 1H~
7~2 ts~ 51~) S ExaMple 39 N~(1-S Carboxy-3-phenylpropyl)-S-alanyl~1S~4S~S~octahydro-cyclohexa~c~pyrrole~1~carboxyl;c ac;d This compound ;s prepared from the compound of Example 33 ;n a method s;milar that descr;bed ;n Example 37.
1H NMR data (CDCl3)~ 1~25 (d~ 3H~
1~3 ~ 4rO (m~ 18H) 4-0 4Y~ (m~ 11-1) 7~2 (s, 511) 5 Example 40 oc~y~c~
N~ S-Carboxy 3 phenylpropyl~-S~alanyl 1S 4R~9$~cyclohexa-Cc~pyrrole-1~carboxyl;c acid This compound is prepared from the compound of Example 34 ;n a method similar to that describecl in Example 20 37~
1H Ni~R daLa (CDCl3): 1.3 (d~ 3H) 1.3 - 4.0 (m 1~H) 4.0 ~ ~6 (m~ 1H) 7.2 (s 5il) Example 41 N-(1 S~Carboxy~3-phenylpropyl) S~alanyl--1S~4S 10S~(iecahydro-~
cycloheptaCc~pyrrole~1-calboxylic acid This compound is prepared flom the compound o Example 35 in a methoc similar to that described in Example 37.

~H NMR data (C~Cl3~: 1.2 (d, 3H) 1.3 ~ 4.0 (m, 20H) l~.0 - 4.5 (m, 1H) 7~2 ~s~ SH) Example 42 N-(1~S-Carboxy-3 pl-enylpropyl)~S-alc7nyl-1S,4R,,lOS decahydro-cyclohepta[c~pyrrole~1~carboxylic acid Thls compound is prepared from the cornpound o-F
Example 36 ;n a method similar to that described in ~xample 37.
1H NMR data (CDCl3): 1.2 (d~ 311) 103 4~0 (m, 20H) 4.0 - 4.5 (m~ 1H) 7.2 (s, 5H) Example 43 Benzyl N-(1-S-carbctho~y-3 phellyl-3-oxo~propyl) S~alanyl-1S~4S,8S-octahydrocycloperlta~cipyrrole-1-carboxylate 2.5 g of N~ S-carbethoxy~3~phenyl-3-oxo-propyl)-S-alaniner 1.2 g of 1-hydroxybenzotria20le, 2 5 g of benzyl (~)-1S,4S,8S-octahydrocyclopentai~c]pyrrole-1~carboxylate hydrochloride, 1.25 ml of N-~thylmorpholine and 2 g of di-cyclohexylcarbodi;m;de are added to 20 ml of dimethylform-am;de. The mixture is stirred at 0C for 1 hour and then at 20 to 25C for 12 hours.
The reaction solution is diluted Witil 25 ml of ethy~
acetate; precipitated urea is filtered off witll suctionO
The filtrate ;s concenJr~ted ln vacuo~ the resldue is taken up in eth~r, the ethereal solut;on is ~lashed ~;th saturated a~ueous sodiu?l bicarbonate and ll;th ~later, dried~ and ~ 41 ~
concentrated. This gives 3 g of the t;~le compound ;n the fornl of a d;astereoisomeric mixture~
1H NMR data (CDCl3) 1.2~ (d~t, 61t) 1.0 ~ 2.8 (m~ 14H) 3.~ 5~1 tm, 6H) 7.2 - S~2 (m, 1~ll) The m;xt~lre of d;astereo;somers can be separated in.o the optically pure compounds over silica gel by using cyclohexane/ethyl acetate as an eluanta Examples b~4 to S0 The following compo~nds, of Examples 44 to 50, can be prepared from the corresponding bicycl;c carboxylate com~
pounds ;n a manner s;m;lar to that of Example 43.
Example 44 Ben~yl N-(1 S~carbcthoxy~3-phenyl~3-oxo-propyl)~S-alanyl-~
1S~4R~8S~octahydrocyclopenta[c~pyrrole-1 carboxylate 1H NMR data (CDCl~): 1.25 (d+t, 6H) 1~3 r~ z~4 (m, 6H) 2.4 - 3 ~ (m, 8H) ~.2 (~, 2H) 4~3 - 4n8 (mr 1H) 5.2 (s, 2H) 7.2 (s, SH) 7.4 - ~.1 (m, SH) Example 45 ~enzyl N (1 S-carbethoxy~3-phenyl 3~oxo~propyl)-S-alanyl~
1Sr45~9S~octal-ydrocyclohexa~cIpyrrole-1-carboxylate 1H NMR data (CDCl3): 1 o2 (d, 3H) 1.3 (t, 3H) 1.3 - 2.4 (m, 8H) ZO4 - 3u8 (m, 8H) 4.1 tq, 2H) 4O3 4.8 (m, 1H) 5.2 (s, 2H) 7.2 - 8~2 (m~ 10H) Example 46 Benzyl N-~1-S-carbethoxy-3-phenyl-3-oxc--propyl)-S-alanyl-. Oc~hyc1~r~7 1S,4R~9S-~yclohexaCc]pyrrole 1~carboxylate 10 H N~lR data (CDCl~): 1.25 (d~ 6H) 1.3 - 2..4 (m, 8H) 2.4 - ~æ (m~ 8 4.1 (q~ 2H~
4.3 - 4.8 (m~ 2H) 5.Z (s, 2~1~
7~1 - 8.2 (m~ 10H) Example 47 Tert.-butyl N-(1-S-carbethoxy-3-phenyl-3 oxo~propyl)~S
c~c~ h~
alanyl-1S,4Sf8S-lcyGlopelltaCcIpyrrole-1~carboxyla~e 20 1H NMR data (CDCl3): 1~25 (d+t, 6H) 1u3 (s, 9H~
1.3 ~ 2~4 ~m~ 6H) 2.4 - 30æ (nl~ 8~1) 4.1 (q~ ZH) 4.3 - 4.8 (m, 1H) 7.2 - s~n (m,~ Sl-l) ~L~9~

43 ~
Example 4 Terto~butyl 1~ S-carbe~:hoxy-3~-phenyl-3-oxo-propyl~-S~
alanyl-1S,4R~8S~octahydrocyclopentaCc~pyrrole-1~carboxylate 1H NMR da~a (CDCl3): 1~3 (d~t, 6H) 1.35 (s, 9H) 1~4 ~ 2~5 (m~ bH) 2~5 ~ 3~8 (m~ 8H) 4n15 (q~ 21-l) 4 ~ n 8 t M, 1 ~1 ) 7.2 - 800 ~m, 5H) Example 49 Tert.-butyl N-(1~S-carbechoxy~3-phenyl~3-oxo~propyl.)~S-alanyl--1S,4SfSS octallyclrocyclohexa[c]pyrrole-1-carboxylace 1H NMR data (CDCl~): 1.3 ~d~c, 6H) 1 4 (s, 9H) 1~4 ~ 2n5 (m~ 8H) 2~5 3~ (m, 8H) 4~2 ~q~ 2~) 4 n3 4 ~8 (m, 1H) 7.3 8.1 (m, SH) Example 50 Bucyl r~-(1 S carbethoxy-3-phenyl-3-oxo-propyl)-S alanyl~
1S,4R,9S-octahydrocyclohexaCc]pyrlole-1~carboxylate 1H NMR data (CDC l3)~ 1o2 (d~t, 6H) 1~3 (s,,. 9H~
104 - 2~6 (rnO ~H) 2~6 ~ 3~9 ~m~ n~l) 4=2 ~q~ 2H) 4.3 - 4~ tm~ 1H) 7~13 ~ 8n1 (m~ 5H) 4~ -~xample 51 N-(1 S Carbethoxy-3~pllenyl-3-oxo propyl)-S-alanyl-1S,4S~S~
octahydrocyclopentatc]pyrrole-1~carboxylic acid 0.9 t1 of the compound ~f Example 47 are st;rred at 20C for 2 hours in 6 ml of tri-fluoroacet;c acid. The solution is concentrated in vacuo~ and the residue is tritura~ed ~ h diisopropyl ether and filtered of~ ~ith suct1on.
Yield: 0.4 9~
11l NMR data (CDCl3). 1.2 (d-tt, 6H) 1.3 - 3.6 (m, 12H) 4.2 (q, ~) 4.1 - 4.6 (m, 4H) 7~3 - 8~1 (m~ 511) The compounds of Examples 52 to 54, which -follou~
can be prepared in a manner similar to that described in ~Example 51:
Example 5~
N~ S-Carbethoxy~3-phenyl-3~oxo-propyl)-S~alanyl-1Sr4~,8S-octahydrocyclopentarc]pyrrol.e-1-carboxylic acid 20 1H NrlR data (CDCl3): 1.25 (d-~t, 61-l) 1.3 - 306 tmr 12H) 4.2 t~ ?H) 4o1 ~ 406 (mr 4H) 7~3 - 8.1 (rn~ 5H) Example 53 N-(1-S-Carhethoxy~3-phenyl~3~oxo-propyl)~S-alanyl~1Sr4S,95-octahyclrocyclohexaCc]pyrrole-1^ca.rboxyl;c acicl 1H NM~ data (CDC l3) 1~3 td~t~ 6H) 1~3 - 3~6 (m, 14H) 4.2 (q, 211) 4 ~ o 6 ( m ~
7=3 - ~1 (m~ 511) Example 54 N~ S-Carbetl)oxy~3~phenyl-3-oxo-propyl)-S~al.anyl 1S,~tR,9S-octahydrocyclohexaCc]pyrrole 1-carboxylic acid 1H NM~ da~a (CPCl3)~ 1.3 (d~tf 6H) 1~ - 3~6 (m, l4H) ~.2 (q~ 2~) 4.1 - 4.6 (r,l, 4H) 7~3 ~ 8 1 ~m, 5~l) Example 55 N-(1-S-Carbethoxy-3~phenyl~3~oY.o-propyl)-S~alanyl~1S~4Sr8S-oc~ahydrocyclopenta[c]pyrrole-l-carboxylic acid 15 This compound is prepared by reacting 0~5 g of N~
S-carbe'choxy 3-phenyl~oxo-propyl)-S-alanyl-lS,4Sr8S-octahydrocyclopenta~c~pyrrole-1~carboxyl.ic acid with potassiuln hydroxide ;n a rnanner similar to that described in Example 37:
20 1ll NM~ data (CDCl3) 1.2 (d~ 3H) 1.2 3O8 (m, 14H) 4.0 - 4u6 (m, 1H) 7O2 - 7=9 (m, SH) Example 56 25 N-~1-S-Carbethoxy-3~phetlyl~3~hydroxypropyl)~S~alanyl-1S,~tSr8S-octahydlocyclopentaCc~pyrrole~1-carboxylic ac;d 1 g of N-(1-s-carbe1:hoxy-3-phenyl 3voxo~propyl)-S~
alanyl-1S~4S~8S-octahydrocyclopentaCc~pyrrcle~ carboxylic acia is dissolved in 50 ml o-F anhydrcus e-thanolr and ll9B3L:l~
~ ~6 hydrogenated a~ 20 to 25C under atmospheric pressure ~ith 1 mole equivaler,~ o-f hydrogen usin~ SO rng of palladium/char coal. The catalyst ;s f;ltered oFF, the solut;on is evapor~
ated to dryness, and the residue is triturated with diiso propyl ether and filtered oFf ~ith suction.
~'ield: 0.7 9.
1H NM~ data (CDCl3)o i n3 (d~t, 6H~
1~3 - 3.6 ~m, 12~') 4~2 (q, 2~1) 4u1 - 406 (m~ 4H) 4.8 (d, 1H) 7.0 ~ 7.5 (m, 5H) Example 57 Benzyl S-alanyl~1S~S~8S~oc~ahydrocyclopeniaic~pyrrole-1-carboxylate a) Ben~yl N-tertc-butoxycarbonyl-S~alanyl~1S,~S,8S-octahydro-cycloDenta[c~pyrrole~1 carboxylate 13 ml of N-etllylmolpilvline, 13~5 g of 1-hydroxyben~o-triazole and 29.6 g of benzyl 1S~4S,SS--octahydrocyclopenta ~c]pyrrole-1-carboxylate hydrochloride are added to a sol-ut;on of 19 9 of BOC-Ala-OII in 100 rnl oF D~lF~ The mixture ;s cooled in an ice bath, and 21 g of dicyclohexylcarbodi~
imide are added to it. The resultincJ mixture is st1rred at 20 to 25C for 15 hours. The precipitated urea is f;l~
tered off ~ith suction, the Filtrate is concentrated in vacuo~ and the residue is taken up in ethyl acetate~ The organic phase is extracted 3 times each ~ith aqueous potas~
sium hydro~e~sulFate, potaC;sium hydr~encarborlate and sodium chloride~ dried~ alld evaporated to dryr,ess~ The residue is is chromatographecI over s;l;ca ~el ~;th ethyl acetate/cyclo~
hexane ~1:3)~ TI1e first fract;on conta;ns the des;red product.
Yield: 21 ~.
1H NMP~ data (CDCl3): 1.3 (d, 3H) 1045 ts~ 91~) 1.1 - Zu4 (m~ 8H) 3.2 - 3~9 (m, 4H) 5 a 3 ( s ~ 2 ~1 ) 7~ ~s~ 5~
10 b) Benzyl S~alanyl-1S~4S,~S oc~ahydrocyclopeI-taCc~-pyrrole~1-carboxyl3te 20~5 9 o-f benzyl N-te,t~-butoxycarbonyl S-hlanyl 1S,4S,~S-octahydrocyclopenta~c]py,-role-1-carboxylate are dissolved in 50 ml of tr1fluoroacetic acid~ The solution is reacted fGr 10 minutes and then concentrated in vacuo, and the residue is triturated several t;mes with diisopropyl ether, and dried in vacuo.
Yield: 12~5 ~
Examples 58 to 62 These compounds are prepared in ways simiLar to those described in Exarnple 57 under a3 and b):
Example 58 Benz~l S-alanyl-1S,~R,8S octahydrocyclopenta~c~pyrrole-1 carboxylate 25 1II N,lR data (C~5l3): 1.3 ~d, 3H) 1.1 - 2~4 tm~ 8~I3 302 ~ 3~9 (m~ 4H) 5.3 (s, 2~1) 7~4 ~s~ 5H) ~3~
,~ ~
Example 59 Benzyl S--alar.yl~1S,~S~9S-octahydrocyclohexa~c~pyrrole-1 carboxylate 1H NMR data tCDCl3): 1.3 (d~ 311) 1.3 - 2.6 (m, 10H) 3.2 - 3~9 tm~ l.H) 5~3 (5r 2H) 7O~ (s~ 5~I) Example oO
Benzyl ~-alanyl-1S~4Rj~S-octahydrocyclohexa~c:lpyrrole~1 carboxylate 1H NMP~ data tCDC l3) 1~3 (d, 3H) 1.3 - 2.5 (m, 1~H) 3.1 - 3.9 (m~ 4H~
5.2 (s, 2H) 7.4 (sO 5H) Example 61 Benzyl S~alanyl 1S,4S,10S~decahydrocyclohep~aCc~pyrrole~1 carboxylate 1It NMR da~a tCDCl3): 1.3 td~ 3H) 1.3 2~7 ~m, 1211) 3.1 3.9 (rn, ~H) 5.2 (s, 2H~
7.4 (s~ 5H) Example 62 Ben.~yl S~alar,yl 1S~.Rr10S-decahydrocycloheptaCc]pyrrole-1 carboxylate 1H NMR data (CDCl3~ 3 (d~ 3H~

1rr3 ~~ 2~8 fmr 1ZH) 3.1 3.9 (m, I~H) 5.2 (s, 2H) 7~4 (s~ 5~1) Example 63 N~ S-Carbethoxy~3~phenylpropyl)~S~alanyl~1S~tSs.8S-octa-hydrocyclopentaCc3pyrrolP-1-carboxylic acid a) ~en~yl ~-(1 S~carhe-thoxy~3-phenylpropyl)-~S--alanyl-1S~4S~aS-octahydrQcyclopenta~c:lpyrrole-1~carboxyla~ie 10 rnrnoles o-f benzyl S--alanyl 1S~-'tS~8S~octahydro-cyclopentaLc~pyrrole 1-carboxyla~e are dissolved in 30 rnl of anhydrous ethanol~ The solution is adjusted to pl~ 7.0 by means of ethanolic potass;um hydroxider and 1 ~ of- pulver ized molecular sieve (4R) and then 10 mrnoles o-F ethyl 2~keto-4-pllenylb~ltyrate are added. A solution of 1 ~ of sodium cyanoborohydride in 10 ml of anhydrous cthanol are slowly added dropwis2. The react;on solution is reacted at 20 to 25C for 2~ hours and then f-iltered~ and the solvent is distilled o~f~ The residue is talen up in ethyl accta~e/
~ater~ The ethyl acetate phase is evaporatedr and ihe resi due is chromatographed over silica gel with ethyl acetate~
cyclohexane (1:~). The ~H NMR data agree with the data of the compound of Exanlple 20~
b) Ihe coMpound obtained above ;s converted as described ;n rnethod A of Example 30 into the desired compound~
Example 64 ~en7.yl rl-~1-S carbethc,xy~3 phenyl-3~oxo~propyl)~S-alanyl-15,,llS,,,.9S~oc_ah~/drocyclc)hexal~c'll)yrrole-1 carhoxylate 10 nlrnoles of benzyl S--alanyl~1 S~4Sr9S octahyclrocyclo~

penta[c~pyrrole~ carboryla~e~ 10 rnmoles of 3 ethyl ben~oyl acrylate and 10 mmoles of triethylamine are dissolved in 100 ml o-f anhydrous ethanol~ and the mixtule is stirred at 20 to 25C for 2C~ hours. It is neutralized w;th 1 N hydro-chloric acid, and evaporated t~ dryness~ and the residue is taken up in ethyl acetate/waterO ~he ethyl acetate phase ;s dried and evaporated to dryness,. and the residue is chroma-to~raphed over s;lica gel~
Example 65 Benzyl N~ S-carbethoxy-3-oxo~3-phenyl-propyl)-1S~I~S~10S~-decatlydrocycloi1e~taCc~pYrrole-1-carboxylate 10 mmoles of acetophenone. 10 mmoles o-f ethyl ~lyoxyl~
ate and 10 mmoles of benzyl S alanyl~1S,~S,10S-decahydrocyclo-hepta[c~pyrrole-1-carboxylate are heated at 45C in ~0 ml of glacial acetic acid for 3O hours. The mixture is concentr~ted in vacuo, renoered alkaline with aqueous so~ium bicarbonateg and extracted ~ith e-thyl acetate. The ethyl acetate phase ;s evaporated to dryness, and the residue is chromatographed over silica gel.
Example 66 2n N~ S-Carbetlloxy~3 pherlylpropyl)-O ethyl-S-tyros~Jl~ 1Sr/~S,~gS-octahydrocyclopenta~c~pyrrole-1 çarboxylic acid a) Benzyl N-~1 R~S-carbethoxy-3-phenylpropyl)~0 ethyl-S-tyrosyl ester 24 9 of ethyl benzoylacrylate are reacted in 1C0 ml of ethanol h~ith 30 g of benzyl 0-ethyl S-tyrosine ester in the presence of O~S ml of triethylamine~ the mixturc is con-centrated to dryness, and the residue ;s taken up ~ith dieth>l etl1er/petroleum ethe~ 1) and dried in vacuo, to g;ve ~2 g of the title compound~

b~ N~ R~S Carbethoxy-3-phcrlylpropyL)-n~etllyl~S~tyros;ne ~ 0 g of the comF)ound obta1ned in Example 66a are hydrogenated at room temperature and under 100 bar in 800 ml of glacial acet;c ac;d us;ng 4 ~ of Pd/C (10%)~ Chromato-graphy over silica gel using ethyl aceta.e/cyclohexane (1:3)as eluant and drying of the residue of evaporation give 25 9 of the title compound in a form ~/hich is alrnost pure by thin layer chromatography and has a melting point of 205-C22H29N05(39~5) Calculated C 6~.15 ll 7~31 N 3~50 Found C 69uS H 7n~ N 3~3 c) N~ S~Carbethoxy 3~phenylpropyl~ 0 ethyl~S tyrosyl-1S~4S 8S octahydlocyclopentaCc~pyrrole~1-carboxylic acid 1.5 g of the benzyl ester described in Example 10 are reacted in a manner similar to that descr;bed in Example 20 ~lith 2.5 9 of N (1 R S-carbethoxy 3~phenylpropyl)-3 ethyl-S~tyrosine 1.3 9 of dicyclohexylcarbodi;lll;de and 0~ g of 1-hydroxybenzotriazole. Chromatography of the crude product over s;lica gel using cyclohexane/ethyl acetate (1:1) as eluan~ gi~es 1 9 of the title compound in the form of a col-orless oil.
The 1H NMR data and the mass spectrum are in accord ith the ind;cated structure~
The benzyl ester is hydrogenolyzed in a manner similar to that described ;n Example 30. This ~ives 006 9 of the title compolnd in the forrn of a colorles amorphous powder;
H NMR data. 7.3 ~s 5H)~
7~1 6 5 (2d~ llH)d 4~4 ~ 'tuC (m~ 4H);

~~ 52 3~9 3nU (m, 4~
2~9 ~ 1~2 (m, 15H);
1.4 (t, 3H);
1~25 (t, 3H)o5 Example 67 N-(1-S~Carhethoxy-3-phenylpropyl)-0 methyl-S tyrosyl-1S~4S~8S-octahydrocyclopentaCc~pyrrole-1 carboxylic acid The title compound is obtained in a manner similar to that described ;n Example 66 by using benzyl O-me-thyl 1n tyrosine ester in place o, benzyl O-ethyltyros;nc ester in the stage analogous to 56a, L
1H NMR data: 7L2(S~ 5H);
7.16.5 (2d, 4H)~
~n O ( m, 31~)~
~3~0 (rn, 3li);
~5(s, 31~);
2.9 - 1.2 (m, 15H);
1.3 (t, 3H)~
Examp~e 6~
20 N~ S-Carbethoxy-3 phenylpropyl?~O ethyl-S-tyrosyl 1S,LSr9S-octahydro;soindole-1~carboxylic acid Prepared in a manner similar to that described in Example 66 from the aminoacid described in Example 2r The 1l-l NMR data agree with the indicated structure~
Example 69 N~ S Carbethoxy~3~phenylprop)~ 0-methyl~ tyrosyl~1S~4S~9S~
octahydro;soindole-2~carboxylic acid Prepared in a manner similar to that o'escribed in ~xaMple 6~ frorn the aminoacid described in Example 2. The H NMR data agree with the indicated structure~
Example 70 N~ S-Carbethoxy-3-phenylpropyL)-0-ethyl-S tyrosyl-1S~4S,8R-octahydrocyclopenta[c]pyrrole-l-carboxylic acid Prepared in a manner sim;lar to that described in Example 6~ from the aminoacid described in Example 7.
1H NMR data: 7.3 (s, 5H);
7.2 - 6~6 ~2d, 4H);
4.4 - 3.9 (m, 4H)~
3~9 3.0 (m, 4H~;
2 ~9 ~ 1 r2 (m, 15H~;
1.35 (t, 3H)9 1925 (t, 3H~.
Example 71 15 N-(1-S-Carbethoxy 3-phenylpropyl)-0 methyl-S-tyrosyl-1S94S,8R
octahydrocyclopentaCc]pyrrole-1 carboxyLic acid Prepared ;n a manner s;m;lar to that described in Example 67 from the aminoacid descr;bed in Example 7. The 1H NMR data agree w;th the indicated structureD
ExampLe 72 N~ S-Carbethoxy-3-phenylpropyl)-D-ethyl-S-tyrosyl~1S~45,9R-octahydrocyclohexaCc~pyrrole-1-carboxy~;c acid Prepared in a manner similar to that described ;n Example 66. The analyt;cal data agree w;th the indicated structure.
Example 73 N-~1-S-Carbethoxy-3-phenylpropyl)-O~methyl-S-tyrosyl-1S,4S,9R-vctahydrocyclohexaCc~pyrrole~1~carboxyl;c ac;d Prepared in a manner similar to that described in .~

Example 67. The analytical cla~a a~ree wi~h l:l~e inclical:ed ~trucl:ure~

Claims (6)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for the preparation of a compound of the formula I

I

wherein the hydrogen atoms at the bridgehead carbon atom 4 and (7+n) are in a cis or trans configuration relative to each other, and the carboxyl group on carbon atom 1 can be in a cis or trans configuration relative to the hydrogen atom on carbon atom (7+n), and wherein n = 1, 2 or 3, R1 = hydrogen, (C1-C6)-alkyl which may be substituted by amino or (C1-C4)-acylamino, or benzoylamino, (C2-C6) alkenyl, (C5-C9)-cycloalkyl, (C5-C9)-cycloalkenyl, (C5-C7)-cycloalkyl-(C1-C4)-alkyl, (C6-C10)-aryl or partly hydrogenated (C6-C10)-aryl, either of which can be substituted by (C1-C2)-alkyl, (C1-C2)-alkoxy or haloyen, (C6-C10)-aryl-(C1-C4)-alkyl, the aryl radical of which can be substituted as defined above, or side chain of a naturally occurring aminoacid, R2 = hydrogen, (C1-C6)-alkyl, (C2-C6)-alkenyl or (C6-C10)-aryl-(C1-C4)-alkyl, Y = hydrogen or hydroxyl, Z = hydrogen or Y and Z together = oxygen, X = (C1-C6)-alkyl, (C2-C6)-alkenyl, (C5-C9)-cycloalkyl, (C6-C10)-aryl which can be monosubstituted, disubstituted or trisubstituted by (C1-C4)-alkyl, (C1-C4)-alkoxy, hydroxyl, halogen, nitro, amino, (C1-C4)-alkylamino or di-(C1-C4)-alkylamino and the physiologioally acceptable salts thereof.
in which (a) a compound of the formula II

II

wherein R1, R2, X, Y and Z are as defined in the formula I, is reacted with a compound of the formula III

III
in which the configuration of the bicyclic ring system and of the substituent on the carbon atom 1 is the same as in the formula I and in which n = 1, 2 or 3 and W = a radical which can be eliminated by hydrogenolysis or under acidic conditions, and the radical W is eliminated and, if necessary, the radical R2 is eliminated to give the free carboxyl groups, (b) to prepare a compound of the formula I wherein Y and Z together denote oxygen (b1) a compound of the formula IV

IV
in which the configuration of the bycyclic ring system and of the substituent on the carbon atom 1 is the same and in which n and R1 are as defined as in the formula I

and W is defined as in the formula III, is reacted with a compound of the formula V

R2O2C - CH = CH - CO - X V

wherein R2 and X are as defined in the formula I, and the radical W is eliminated and, if necessary, the radical R2 is eliminated to give the free carboxyl group, or (b2) a compound of the formula IV mentioned under (b1) is reacted with a compound of the formula VI in which R2 is as defined in the formula I and with a compound of the formula VII

(VI) (VII) wherein X is defined as in the formula I and the radical W is eliminated and, if necessary, the radical R2 is eliminated to give the free carboxyl groups, or (c) to prepare a compound of the formula I wherein Y and Z each denote hydrogen, (c1) a compound of the formula IV mentioned under (b1) is reacted with a compound of the formula VIII

VIII

wherein R2 and X are defined as in the formula I, the Schiff's base obtained is reduced and the radical W is eliminated and, if necessary, the radical R2 is eliminated to give the free carboxyl groups, or (c2) a compound of the formula I wherein Y and Z
together denote oxygen is reduced, or (d) to prepare a compound of the formula I wherein Y =
hydroxyl and Z = hydrogen a compound of the formula I
wherein Y and Z together denote oxygen is reduced and the compound of the formula I in variants (a) to (d) may be converted into their physiologically acceptable salts.
2. A compound of the formula I as defined in claim 1, whenever obtained according to a process as claimed in claim 1 or by an obvious chemical equivalent thereof.
3. A process as claimed in claim 1 in which R1 = hydrogen, (C1-C3)-alkyl, (C2-C3)-alkenyl, benzyl, 4-aminobutyl, 4-methoxybenzyl or 4-ethoxybenzyl, R2 = hydrogen, (C1-C4)-alkyl or benzyl, and X = phenyl which can be monosubstituted or disubstituted by (C1-C2)-alkyl, (C1-C2)-alkoxy, hydroxyl, fluorine, chlorine, bromine, amino, (C1-C4)-alkylamino, di-(C1-C4)-alkylamino, nitro or trisubstituted by methoxy.
4. A compound of the formula I as set forth in claim 1 where n, Y and Z are as defined in claim 1 and R1, R2 and X are as defined in claim 3, whenever obtained according to a process as claimed in claim 3 or by an obvious chemical equivalent thereof.
5. A process as claimed in claim 1 in which n = 1 or 2, R1 = methyl, 4-methoxybenzyl or 4-ethoxybenzyl, and X = phenyl.
6. A compound of the formula I as set forth in claim 1 wherein R2, Y and Z are as defined in claim 1 and n, R1 and X are as defined in claim 5, whenever obtained according to a process as claimed in claim 5 or by an obvious chemical equivalent thereof.
CA000424770A 1982-03-30 1983-03-29 Derivatives of cycloalka[c]pyrrolcarboxylic acids, a process for their preparation, agents containing these compounds, and their use, and new cycloalka[c]pyrrolcarboxylic acidsas intermediates, and a process for their preparation Expired CA1198118A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3211676.4 1982-03-30
DE19823211676 DE3211676A1 (en) 1982-03-30 1982-03-30 NEW DERIVATIVES OF CYCLOALKA (C) PYRROL CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF AND NEW CYCLOALKA (C) PYRROL CARBONIC ACIDS AS THE INTERMEDIATE LEVELS AND METHODS

Publications (1)

Publication Number Publication Date
CA1198118A true CA1198118A (en) 1985-12-17

Family

ID=6159702

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000424770A Expired CA1198118A (en) 1982-03-30 1983-03-29 Derivatives of cycloalka[c]pyrrolcarboxylic acids, a process for their preparation, agents containing these compounds, and their use, and new cycloalka[c]pyrrolcarboxylic acidsas intermediates, and a process for their preparation

Country Status (17)

Country Link
EP (1) EP0090362A3 (en)
JP (1) JPS58177967A (en)
KR (1) KR840004069A (en)
AU (1) AU560124B2 (en)
CA (1) CA1198118A (en)
DE (1) DE3211676A1 (en)
DK (1) DK144783A (en)
ES (2) ES8401937A1 (en)
FI (1) FI831049L (en)
GR (1) GR78157B (en)
HU (1) HU193876B (en)
IL (1) IL68267A (en)
NO (2) NO831168L (en)
NZ (1) NZ203719A (en)
PH (1) PH19003A (en)
PT (1) PT76472B (en)
ZA (1) ZA832229B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226768A1 (en) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF
NZ202903A (en) * 1981-12-29 1988-01-08 Hoechst Ag 1-- pe pyrrol-2-yl-carboxylic acid derivatives and pharmaceutical compositions
DE3246503A1 (en) * 1982-12-16 1984-06-20 Hoechst Ag, 6230 Frankfurt DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (5.3.0) -DECAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THESE AGENTS AND THE USE THEREOF
US5175306A (en) * 1983-01-31 1992-12-29 Hoechst Aktiengesellschaft Process for the resolution of racemates of optically active bicyclic imino-α-carboxylic esters
DE3303344A1 (en) 1983-02-02 1984-08-02 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED AMINO ACIDS AND THEIR ESTERS
FI841052A (en) * 1983-03-16 1984-09-17 Usv Pharma Corp FOERENINGAR FOER BEHANDLING AV BLODTRYCKSSJUKDOMAR.
FR2546886B2 (en) * 1983-06-06 1986-05-16 Adir DERIVATIVES OF ISOINDOLEDICARBOXYLIC ACIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE3333455A1 (en) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED DIPEPTIDES AND THEIR ESTERS
DE3333454A1 (en) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED DIPEPTIDES AND THEIR ESTERS
DE3410732A1 (en) * 1984-03-23 1985-09-26 Hoechst Ag, 6230 Frankfurt METHOD FOR TREATING GLAUCOMA
DE3413710A1 (en) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt METHOD FOR TREATING HEART INSUFFICIENCY
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
EP0190224A1 (en) * 1984-07-30 1986-08-13 Schering Corporation PROCESS FOR THE PREPARATION OF CIS, ENDOOCTAHYDROCYCLOPENTA [b] PYRROLE-2-CARBOXYLATE
DE3431541A1 (en) * 1984-08-28 1986-03-06 Hoechst Ag, 6230 Frankfurt CIS, ENDO-2-AZABICYCLOALKAN-3-CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND INTERMEDIATE PRODUCTS IN THEIR PRODUCTION
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
DE3633496A1 (en) * 1986-10-02 1988-04-14 Hoechst Ag COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH CALCIUMANTAGONISTS AND THEIR USE IN MEDICINAL PRODUCTS
DE3639879A1 (en) * 1986-11-21 1988-06-01 Hoechst Ag METHOD FOR PRODUCING MONO, BI AND TRICYCLIC AMINO ACIDS, INTERMEDIATE PRODUCTS OF THIS METHOD, AND A METHOD FOR PRODUCING THE SAME
DE3722007A1 (en) * 1987-07-03 1989-01-12 Hoechst Ag METHOD FOR PRODUCING BICYCLIC AMINOCARBONIC ACIDS, INTERMEDIATE PRODUCTS OF THIS METHOD AND THE USE THEREOF
JPH0278659A (en) * 1988-09-12 1990-03-19 Shionogi & Co Ltd Compound of azabicycloalkanes
DE3839127A1 (en) * 1988-11-19 1990-05-23 Hoechst Ag PYRROLIDONE-2-CARBONIC ACID DERIVATIVES WITH PSYCHOTROPER EFFECT
DD284030A5 (en) 1988-11-24 1990-10-31 Hoechst Ag,De PROCESS FOR THE PREPARATION OF PEPTIDES WITH BRADYKININ-ANTAGONISTIC EFFECT
LT3872B (en) 1993-12-06 1996-04-25 Hoechst Ag Novel peptides and pharmaceutical compositions containing them
FR2746394B1 (en) 1996-03-20 1998-05-29 Roussel Uclaf NOVEL TRICYCLIC COMPOUNDS, THEIR PREPARATION PROCESS, AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE59706273D1 (en) 1996-03-20 2002-03-21 Hoechst Ag Bone resorption inhibitors and vitronectin receptor antagonists
BR9712544B1 (en) 1996-10-18 2013-10-22 SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
DE19741235A1 (en) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
DE19741873A1 (en) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh New 5-ring heterocycles, their preparation, their use and pharmaceutical preparations containing them
DE19751251A1 (en) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituted imidazolidine derivatives, their manufacture, their use and pharmaceutical preparations containing them
DE19821483A1 (en) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
EP2364970A1 (en) * 2005-08-19 2011-09-14 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
JP5436864B2 (en) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Co-crystal containing VX-950 and pharmaceutical composition containing the same
EP1993994A2 (en) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
NZ579295A (en) 2007-02-27 2012-03-30 Vertex Pharma Inhibitors of serine proteases
SI2114924T1 (en) 2007-02-27 2012-06-29 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
CN101835774B (en) 2007-08-30 2014-09-17 弗特克斯药品有限公司 Co-crystals and pharmaceutical compositions comprising the same
WO2010008828A2 (en) 2008-06-24 2010-01-21 Codexis, Inc. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
JP5829529B2 (en) * 2011-08-29 2015-12-09 日本曹達株式会社 Optically active quaternary ammonium salt and method for producing optically active compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
FR2487829A2 (en) * 1979-12-07 1982-02-05 Science Union & Cie NOVEL SUBSTITUTED IMINO ACIDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
DE3174844D1 (en) * 1980-10-23 1986-07-24 Schering Corp Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
DE3276311D1 (en) * 1981-02-17 1987-06-19 Warner Lambert Co Octahydro-2-(omega-mercaptoalkanoyl)3-oxo-1h-isoindole-1-carboxylic acids and esters
ZA826022B (en) * 1981-08-21 1983-08-31 Univ Miami Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides
EP0081094A1 (en) * 1981-11-12 1983-06-15 Merck & Co. Inc. Substituted omega-amino-carboxymethyldipeptide antihypertensive agents
DE3360065D1 (en) * 1982-03-08 1985-03-28 Schering Corp Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JPS58177967A (en) 1983-10-18
PT76472A (en) 1983-04-01
DE3211676A1 (en) 1983-10-06
NZ203719A (en) 1986-02-21
KR840004069A (en) 1984-10-06
ZA832229B (en) 1983-12-28
DK144783D0 (en) 1983-03-29
FI831049L (en) 1983-10-01
FI831049A0 (en) 1983-03-28
ES521741A0 (en) 1984-02-01
EP0090362A3 (en) 1985-09-18
DK144783A (en) 1983-10-01
ES521041A0 (en) 1984-01-01
PT76472B (en) 1986-01-24
GR78157B (en) 1984-09-26
EP0090362A2 (en) 1983-10-05
AU1297083A (en) 1983-10-06
AU560124B2 (en) 1987-04-02
HU193876B (en) 1987-12-28
IL68267A (en) 1987-03-31
PH19003A (en) 1985-12-03
ES8402570A1 (en) 1984-02-01
NO834352L (en) 1983-10-03
IL68267A0 (en) 1983-06-15
NO831168L (en) 1983-10-03
ES8401937A1 (en) 1984-01-01

Similar Documents

Publication Publication Date Title
CA1198118A (en) Derivatives of cycloalka[c]pyrrolcarboxylic acids, a process for their preparation, agents containing these compounds, and their use, and new cycloalka[c]pyrrolcarboxylic acidsas intermediates, and a process for their preparation
KR900007241B1 (en) Process for preparing bicyclic amino acids derivatives
CA1341196C (en) Process for the preparation of substituted imino diacids
CA1205476A (en) Substituted acyl derivatives of octahydro-1h-indole-2- carboxylic acids
CA1210768A (en) Derivatives of cis, endo-2- azabicyclo[5.3.0]decane-3-carboxylic acid, a process for their preparation, agents containing these derivatives and their use
US4822894A (en) Optically active bicyclic imino-alpha-carboxylic esters
JPH0694443B2 (en) Amino acid derivative
EP0031741A1 (en) Substituted imino-acids, process for their preparation and their use as enzyme inhibitors
GB1572688A (en) Spirohydantoins
JPH064586B2 (en) Novel bicyclic compound
KR910003185B1 (en) Processes for preparation of spirocyclic aminoacid derivatives
WO1993012786A1 (en) Indolinone derivatives
JPS58177968A (en) Azaspiro-carbonic acid derivative
JPS5929686A (en) Novel derivatives of 2-azabicyclo(2,2,2)octane- 3-carbonic acid and manufacture
US5359086A (en) Process for preparing alkyl-L-alanyl-L-proline derivatives
SU1327787A3 (en) Method of producing cis,endo-2-azabicyclo-(3,3,0)-octane-3-carboxylic acids or acid-additive salts thereof
KR910001438B1 (en) A process for the resolution of racemates of optically active bicyclic imino-alpha-carboxylic esters
US3679699A (en) CIS-2-ACETYL-1-METHYL-1,2,3,3a,4,9b-HEXAHYDRO {8 1{9 BENZOPYRANO {8 4,3-C{9 PYRAZOLE
JPS59130268A (en) Novel 2-azabicyclo(2,2,1)heptane derivative
JP3202234B2 (en) New process for producing 2-fluoropurine derivatives
WO1980000444A1 (en) Hydroxamic acid derivatives
KR930008630B1 (en) Novel derivatives of bicyclic amino acid and its production
US5175306A (en) Process for the resolution of racemates of optically active bicyclic imino-α-carboxylic esters
US4405787A (en) 3-Carboxy-2-azabicyclo[2.2.1]heptane derivatives
US4034045A (en) 2,4-Disubstituted-4b,5,6,7,8,8a,9,10-octahydro-9-oxo-phenanthrenes

Legal Events

Date Code Title Description
MKEC Expiry (correction)
MKEX Expiry